 |
|
|
| |
EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients
|
| |
| |
EASL 2022 June 22-26
Man-Fung Yuen1, Wan-Long Chuang2, Cheng-Yuan Peng3, Wen-Juei Jeng4,5, Wei-Wen Su6, Ting-Tsung Chang7,8, Chi-Yi Chen9, Yao-Chun Hsu10, Guy De La Rosa11, Alaa Ahmad11, Ed Luo11, Annie L. Conery11, Nathalie Adda11
1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, 2Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 3Center for Digestive Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan, 4Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan, 5College of Medicine, Chang Gung University, Taiwan, 6Department of Gastroenterology and Hepatology, Changhua Christian Hospital, Taiwan, 7Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 8Infectious Disease and Signaling Research Center, National Cheng Kung University, Tainan, Taiwan, 9Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan,10Center for Liver Diseases and School of Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan, 11Enanta Pharmaceuticals, Inc., Watertown, Massachusetts, USA
|
| |
|
|
|
|
|
